Looking for Xtandi (Enzalutamide)?

Xtandi (Enzalutamide) Copay Assistance Information

⏰ COMING SOON

If you or a loved one has been prescribed Xtandi (enzalutamide), understanding your treatment, costs, and assistance options can feel overwhelming. This guide covers what Xtandi is, how it works, side effects to watch for, the latest on generic enzalutamide availability, and copay assistance pathways available to prostate cancer patients today.

QuickRx Specialty Pharmacy is currently preparing to expand our Xtandi (enzalutamide) services in anticipation of generic enzalutamide availability. If you have questions about Xtandi or your prostate cancer treatment, please call us at (917) 830-2525.

Noxafil (posaconazole) copay assistance from QuickRx Specialty Pharmacy

QuickRx Xtandi Financial Support Services — Launching Soon

Untitled Design (5)

QuickRx Copay Assistance

QuickRx Specialty Pharmacy is a URAC- and ACHC-accredited nationwide specialty pharmacy preparing to dispense generic enzalutamide—the generic version of Xtandi—and provide full copay assistance enrollment support for prostate cancer patients nationwide. Xtandi is a once-daily oral androgen receptor signaling inhibitor approved for the treatment of several forms of prostate cancer in adults, including castration-resistant disease in both metastatic and non-metastatic forms, metastatic castration-sensitive prostate cancer, and non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

Xtandi is a high-cost specialty medication, with list pricing exceeding $15,000 per month at the standard 160 mg daily dose. Out-of-pocket costs without assistance can be a significant burden for prostate cancer patients and their families. Once QuickRx begins dispensing generic enzalutamide, our patient navigator team will provide free enrollment support to help connect eligible patients with savings options based on insurance coverage and financial situation.

Our Xtandi financial support services will include:

  • Manufacturer copay card application and enrollment
  • Patient assistance program evaluation and submission
  • Oncology-specific foundation grant research and applications
  • Prior authorization support and appeal assistance
  • Insurance benefit verification
  • Free home delivery of generic enzalutamide to all 50 states

Our team works with patients covered by commercial insurance, Medicare, Medicaid, and those without insurance. To be notified the moment QuickRx begins dispensing generic enzalutamide, call (917) 830-2525 to join our priority notification list.

How QuickRx Will Help with Xtandi Copay Assistance

Affording a specialty oncology medication like Xtandi can feel overwhelming without the right support. Once QuickRx begins dispensing generic enzalutamide, our dedicated patient navigator team will manage your copay assistance enrollment from start to finish—so you can focus on your health.

 ✓ Free enrollment support — no fees, ever

✓ URAC- and ACHC-accredited specialty pharmacy

✓ Licensed and shipping to all 50 states

✓ Dedicated oncology patient navigators on staff

Wallet Filled Money Icon

Xtandi Manufacturer Copay Card

Commercially insured patients may be eligible for a Xtandi manufacturer copay card that can help reduce monthly out-of-pocket costs. Once QuickRx begins dispensing generic enzalutamide, our patient navigators will verify your eligibility and manage the enrollment process on your behalf at no charge.

Patient Assistance Programs

Xtandi Manufacturer Copay Card

Commercially insured patients may be eligible for a Xtandi manufacturer copay card that can help reduce monthly out-of-pocket costs. Once QuickRx begins dispensing generic enzalutamide, our patient navigators will verify your eligibility and manage the enrollment process on your behalf at no charge.

Pills

Oncology Foundation Grants & Additional Financial Resources

Several nonprofit foundations offer financial assistance specifically for prostate cancer patients, which may help cover out-of-pocket costs for medications like Xtandi. QuickRx patient navigators are knowledgeable about available oncology assistance resources and will be ready to identify and apply for funding sources when needed.

*QuickRx provides copay assistance enrollment support as a completely free service. Eligibility for specific programs depends on insurance coverage, income, and other factors. Program availability is subject to change. QuickRx does not currently dispense Xtandi or generic enzalutamide; this page exists to inform patients of our intent to dispense generic enzalutamide once commercially available.

Join Our Priority Notification List for Xtandi

Complete the secure form below to join our priority notification list. As soon as generic enzalutamide becomes commercially available, our patient navigator team will reach out within one business day to verify your coverage and begin identifying available savings programs. You can also contact us directly:

📞 (917) 830-2525

  • This field is for validation purposes and should be left unchanged.
  • PATIENT INFORMATION
  • MM slash DD slash YYYY
  • DOCTOR'S INFORMATION

FAQs

Frequently Asked Questions About Xtandi Copay Assistance
What is Xtandi copay assistance and how does it work?
Xtandi copay assistance refers to financial support programs—including manufacturer copay cards, patient assistance programs, and nonprofit foundation grants—that help reduce the out-of-pocket cost of Xtandi (enzalutamide) for eligible patients. Once QuickRx Specialty Pharmacy begins dispensing generic enzalutamide, we will provide free enrollment support to help identify and apply for programs you may qualify for based on your insurance and financial situation. Eligible patients may pay $0 per prescription depending on insurance and program eligibility.
Who qualifies for Xtandi copay assistance?
Eligibility for Xtandi copay assistance varies by program. Manufacturer copay card programs are generally available to patients with commercial (private) insurance. Patient assistance programs are typically available to patients who are uninsured, underinsured, or whose government insurance (such as Medicare or Medicaid) does not cover the copay card benefit. Once QuickRx begins dispensing generic enzalutamide, our patient navigators will evaluate your specific situation to identify the programs you are most likely to qualify for.
Does QuickRx charge a fee to help me enroll in Xtandi copay assistance?
No. QuickRx Specialty Pharmacy provides copay assistance enrollment support as a completely free service. There are no fees, no hidden charges, and no obligation. Our patient navigator team will assist with your Xtandi application because we believe cost should never be a barrier to treatment.
Can I get Xtandi copay assistance if I have Medicare?
Federal law restricts the use of manufacturer copay cards for patients with Medicare coverage. However, patients with Medicare may still qualify for patient assistance programs or nonprofit foundation grants. The 2025 Inflation Reduction Act also capped Medicare Part D out-of-pocket costs at $2,000 per year, which has substantially reduced the financial burden for many prostate cancer patients on Xtandi. Once QuickRx begins dispensing generic enzalutamide, our patient navigators can review your specific coverage and identify available options.
How can I be notified when QuickRx begins dispensing generic enzalutamide?
You can join our priority notification list by completing the secure form on this page or by calling our patient navigator team directly at (917) 830-2525. The moment generic enzalutamide is commercially available through our wholesaler partners, we will reach out to begin your benefits investigation and prescription transfer at no charge.
What is Xtandi (enzalutamide) used for?
Xtandi (enzalutamide) is a prescription medication approved by the FDA for the treatment of several forms of prostate cancer in adults. This includes castration-resistant prostate cancer (CRPC) in both metastatic and non-metastatic forms, metastatic castration-sensitive prostate cancer (mCSPC), and non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis. Xtandi belongs to a class of medications known as androgen receptor signaling inhibitors, also called second-generation antiandrogens. It works by blocking the effects of androgens such as testosterone on prostate cancer cells.
How is Xtandi taken?
Xtandi is taken by mouth, either as a capsule or tablet, once daily at approximately the same time each day. Xtandi may be taken with or without food. Capsules and tablets must be swallowed whole with sufficient water—they should not be chewed, crushed, opened, or cut. Severe difficulty swallowing has been reported with both forms; patients with swallowing difficulties should discuss this with their prescriber.
What is the dosing schedule for Xtandi?
According to the Xtandi prescribing information, the standard adult dose is 160 mg by mouth once daily. Some drug combinations require dose adjustments. For example, patients taking strong CYP3A4 inducers (such as rifampin or certain seizure medications) may require an increased dose of 240 mg daily. Patients should follow the dosing schedule prescribed by their healthcare provider and consult them if a dose is missed.
How should Xtandi be stored at home?
Xtandi capsules and tablets should be stored at room temperature, between 68°F and 77°F (20°C to 25°C), with brief excursions permitted between 59°F and 86°F (15°C to 30°C). Store in a dry place, protected from moisture, and keep the bottle tightly closed. Do not store Xtandi in a bathroom or other humid location.
What are the most common side effects of Xtandi?
The most commonly reported side effects of Xtandi in clinical studies for prostate cancer include fatigue or weakness (24% to 51% of patients), hot flashes (13% to 27%), back pain (19% to 29%), joint pain (21%), constipation (9% to 23%), decreased appetite (5% to 19%), high blood pressure (6% to 14%), and falls (5% to 13%). Patients should speak with their healthcare provider about any side effects they experience. This is not a complete list of side effects.
Are there serious risks associated with Xtandi?
Yes. Xtandi carries important warnings including the risk of seizures (occurring in less than 1% of patients in general clinical trials, with higher rates in patients with predisposing risk factors), posterior reversible encephalopathy syndrome (PRES), ischemic heart disease, severe allergic reactions including Stevens-Johnson syndrome, and increased risk of falls and fractures. Patients who experience a seizure generally must permanently discontinue Xtandi. This information is for educational purposes only — patients should review all risks with their prescribing oncologist.
Is there a generic version of Xtandi available?
Generic enzalutamide tablets received final FDA approval from Sandoz on April 20, 2026, in 40 mg and 80 mg strengths. Several other manufacturers, including Teva, Zydus, and Humanwell Puracap, have received tentative FDA approval. As of this page’s last update, generic enzalutamide is FDA-approved but not yet widely commercially available in U.S. pharmacies. Market launch delays between FDA approval and pharmacy shelves are common with specialty oncology medications. Key Xtandi patents expire in May and August 2026, which is expected to enable broader commercial availability. QuickRx will dispense generic enzalutamide once it becomes commercially available through our wholesaler partners.
How much does Xtandi cost without insurance?
At list price, brand Xtandi costs approximately $153 per 40 mg capsule or tablet and $307 per 80 mg tablet, which translates to over $15,000 for a one-month supply at the standard 160 mg daily dose. Most patients pay significantly less through insurance, Medicare plans (capped at $2,000 out-of-pocket annually starting in 2025 under the Inflation Reduction Act), or manufacturer and foundation programs. Generic enzalutamide pricing has not yet been established as the medication has not commercially launched.
Does Xtandi interact with other medications?
Yes. Enzalutamide is a strong inducer of the CYP3A4 liver enzyme and may reduce the effectiveness of many medications, including certain blood thinners (such as apixaban and rivaroxaban), seizure medications, blood pressure medications, and other oncology treatments. Enzalutamide is also metabolized by CYP2C8 and CYP3A4, so certain medications may affect Xtandi levels. Patients should inform their healthcare provider and pharmacist about all medications, supplements, and over-the-counter products they are taking.
Does QuickRx currently dispense Xtandi?
Not yet. QuickRx Specialty Pharmacy is preparing to dispense generic enzalutamide once it becomes commercially available through our wholesaler partners. Generic enzalutamide tablets received final FDA approval in April 2026, with commercial launch expected in the coming months. Until then, this page is informational only. QuickRx is a URAC- and ACHC-accredited specialty pharmacy licensed in all 50 states, and once we begin dispensing, we will provide hands-on support for copay card enrollment, patient assistance applications, prior authorization management, and foundation grant coordination—all at no cost to patients. To join our priority notification list, call (917) 830-2525.